CSLLY (CSLLY)
90.10
-0.61 (0.67%)
Latest Headlines
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
April 24, 2024 3:00 AM - PR NewsWire
Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients
March 28, 2024 3:00 AM - PR NewsWire
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
March 19, 2024 7:00 AM - PR NewsWire
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
March 6, 2024 9:01 AM - PR NewsWire
JPMorgan Reiterates Overweight Rating on CSL Ltd. (CSL:AU) (CSLLY)
March 6, 2024 6:31 AM - StreetInsider
Travere Therapeutics (TVTX) and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
February 23, 2024 7:06 AM - StreetInsider
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
February 23, 2024 7:05 AM - Globe NewsWire
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
February 23, 2024 2:00 AM - PR NewsWire
CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD282 at RBC Capital
February 14, 2024 2:09 AM - StreetInsider
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
February 12, 2024 10:54 PM - PR NewsWire
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
February 11, 2024 5:47 PM - PR NewsWire
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
February 5, 2024 8:30 AM - BizWire
Full Article List
